News Treatment for infantile neuroaxonal dystrophy a step closer as Bloomsbury Genetic Therapies receives Orphan Drug Designations
News New hope for Niemann-Pick Disease Type C treatment as Bloomsbury Genetic Therapies receives Orphan Drug Designations
News Bloomsbury Genetic Therapies Receives Rare Pediatric Disease Designation from the U.S. FDA for BGT-INAD for the Treatment of Infantile Neuroaxonal Dystrophy (INAD) and Announces Upcoming Type B Pre-IND Meeting with the U.S. FDA